About Us
Built to discover the biology behind better medicines
Intellomx (Intelligent OMICS Limited) is a UK-based drug discovery company applying proprietary AI and machine learning to human molecular data.
We were established to address a persistent challenge in pharmaceutical R&D: a target can be scientifically interesting without being central to the biology of human disease. Our mission is to uncover the molecular drivers that matter and translate that understanding into more informed discovery programmes.
Scientific depth. Commercial perspective.
The I³ platform builds on longstanding research in computational intelligence, machine learning and systems biology, led by Professor Graham Ball and collaborators. Our management and advisory team combines experience in scientific discovery, technology ventures, strategic partnering and life-sciences transactions.
Our leadership
PROFESSOR GRAHAM BALL — Founder and Chief Scientific Officer — computational intelligence, bioinformatics and systems biology.
DR SIMON HAWORTH — Executive leadership — technology ventures, company development and investment.
DR WILLIAM MASON — Board and commercial leadership — life-sciences strategy, partnering and transactions.
Additional scientific and strategic expertise is provided through our advisers and collaborators.
How we work
We combine rigorous computational analysis with clear scientific questions and practical development objectives. We collaborate with partners to interpret results, define validation experiments and identify the most valuable next decision.
Our ambition
To make the discovery of new disease biology a practical starting point for better target selection, more focused research investment and the creation of future medicines and diagnostics.